Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446271 | 0.82 | GSK3A (0.48) | GSK3AGSK3BALDH1A1LMNAMAPT | |
| SCHEMBL19116813 | 0.77 | HTT (0.40) | GSK3AGSK3BALDH1A1LMNAMAPT | |
| SCHEMBL21335493 | 0.73 | ALDH1A1 (0.40) | GSK3AGSK3BALDH1A1LMNAMAPT | |
| SCHEMBL21335483 | 0.70 | GSK3A (0.58) | GSK3AGSK3BALDH1A1MAPTKMT2A | |
| SCHEMBL19181360 | 0.69 | LMNA (0.45) | GSK3AGSK3BALDH1A1LMNAMAPT | |
| SCHEMBL21335489 | 0.68 | GSK3A (0.41) | GSK3AGSK3BALDH1A1 | |
| SCHEMBL19116985 | 0.68 | GSK3A (0.46) | GSK3AGSK3BALDH1A1 | |
| SCHEMBL19147905 | 0.66 | SIGMAR1 (0.47) | GSK3AGSK3BGRIN2B | |
| SCHEMBL19147613 | 0.65 | GSK3A (0.49) | GSK3AGSK3BALDH1A1LMNAGRIN2B | |
| SCHEMBL19147344 | 0.65 | GSK3A (0.73) | GSK3AGSK3BALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | GSK3A 1263/4885GSK3B 725/4885ALDH1A1 2384/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | GSK3A 1251/4885GSK3B 724/4885ALDH1A1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.